Table 1 Association of miR-548t-5p and CXCL11 expression with clinicopathological features of PDAC.
 |  | miR-548t-5p expression |  | CXCL11 expression |  | ||
---|---|---|---|---|---|---|---|
Variable | Group | High | Low | P-value | High | Low | P-value |
Gender | |||||||
 | Male | 15 | 20 | 0.123 | 19 | 16 | 0.355 |
 | Female | 10 | 5 |  | 6 | 9 |  |
Age (years) | |||||||
 | <60 | 15 | 18 | 0.37 | 16 | 17 | 0.765 |
 | ≥60 | 10 | 7 |  | 9 | 8 |  |
Location | |||||||
 | Head | 15 | 17 |  | 16 | 16 | 1 |
 | Body/tail | 10 | 8 |  | 9 | 9 |  |
T stage | |||||||
 | T1 | 10 | 3 | 0.024* | 2 | 11 | 0.004* |
 | T2 or T3 | 15 | 22 |  | 23 | 14 |  |
N stage | |||||||
 | Absent | 12 | 13 | 0.777 | 9 | 16 | 0.048* |
 | Present | 13 | 12 |  | 16 | 9 |  |
TNM stage | |||||||
 | I | 11 | 10 | 0.774 | 7 | 14 | 0.045* |
 | II–IV | 14 | 15 |  | 18 | 11 |  |
Nerve infiltration | |||||||
 | Yes | 15 | 22 | 0.024* | 22 | 15 | 0.024* |
 | No | 10 | 3 |  | 3 | 10 |  |
Serum CA19-9 (kU/L) | |||||||
 | ≤37 | 14 | 3 | 0.001* | 6 | 11 | 0.136 |
 | >37 | 11 | 22 |  | 19 | 14 |  |
Serum CEA (ug/L) | |||||||
 | ≤5 | 18 | 16 | 0.544 | 17 | 17 | 1 |
 | >5 | 7 | 9 |  | 8 | 8 |  |